Van Cutsem E - Search Results

1

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. De Roock W, et al. Among authors: van cutsem e, van laethem jl. Ann Oncol. 2008 Mar;19(3):508-15. doi: 10.1093/annonc/mdm496. Epub 2007 Nov 12. Ann Oncol. 2008. PMID: 17998284 Free article.

2

Screening for colorectal cancer.

Van Cutsem E, Tejpar S, Rutgeerts P, Janssens J. Van Cutsem E, et al. Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):397-404. Acta Gastroenterol Belg. 1995. PMID: 8775996

3

Pharmacologic therapy of arteriovenous malformations.

Van Cutsem E, Piessevaux H. Van Cutsem E, et al. Gastrointest Endosc Clin N Am. 1996 Oct;6(4):819-32. Gastrointest Endosc Clin N Am. 1996. PMID: 8899412 Review.

4

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

Van Cutsem E, Pozzo C, Starkhammar H, Dirix L, Terzoli E, Cognetti F, Humblet Y, Garufi C, Filez L, Gruia G, Cote C, Barone C. Van Cutsem E, et al. Ann Oncol. 1998 Nov;9(11):1199-204. doi: 10.1023/a:1008478405634. Ann Oncol. 1998. PMID: 9862050 Free article. Clinical Trial.

5

[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].

Van Cutsem E, Peeters M. Van Cutsem E, et al. Bull Cancer. 1998 Dec;Spec No:33-7. Bull Cancer. 1998. PMID: 9932082 Review. French.

6

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Hérait P, Bleiberg H. Van Cutsem E, et al. Among authors: van groeningen c. Eur J Cancer. 1999 Jan;35(1):54-9. doi: 10.1016/s0959-8049(98)00353-0. Eur J Cancer. 1999. PMID: 10211088 Free article. Clinical Trial.

7

Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

Van Cutsem E, Blijham GH. Van Cutsem E, et al. Semin Oncol. 1999 Feb;26(1 Suppl 5):13-20. Semin Oncol. 1999. PMID: 10213010 Clinical Trial.

8

The medical treatment of colorectal cancer: actual status and new developments.

Van Cutsem E, Peeters M, Verslype C, Filez L, Haustermans K, Janssens J. Van Cutsem E, et al. Hepatogastroenterology. 1999 Mar-Apr;46(26):709-16. Hepatogastroenterology. 1999. PMID: 10370599 Review.

9

Developments in fluoropyrimidine therapy for gastrointestinal cancer.

Van Cutsem E, Peeters M. Van Cutsem E, et al. Curr Opin Oncol. 1999 Jul;11(4):312-7. doi: 10.1097/00001622-199907000-00012. Curr Opin Oncol. 1999. PMID: 10416885 Review.

10

Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.

Van Cutsem E. Van Cutsem E. Eur J Cancer. 1999 Mar;35 Suppl 1:S1-2. doi: 10.1016/s0959-8049(99)00040-4. Eur J Cancer. 1999. PMID: 10645206 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

738 results

Search Page

Filters